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Background: Left ventricular hypertrophy (LVH) is common in kidney transplant (KT) recipients. LVH is associated with a
worse outcome, though m-TOR therapy may help to revert this complication. We therefore conducted a longitudinal
study to assess morphological and functional echocardiographic changes after conversion from CNI to m-TOR inhibitor
drugs in nondiabetic KT patients who had previously received RAS blockers during the follow-up.
Methods: We undertook a 1-year nonrandomized controlled study in 30 non-diabetic KT patients who were converted
from calcineurin inhibitor (CNI) to m-TOR therapy. A control group received immunosuppressive therapy based on CNIs.
Two echocardiograms were done during the follow-up.
Results: Nineteen patients were switched to SRL and 11 to EVL. The m-TOR group showed a significant reduction in
LVMi after 1 year (from 62 ± 22 to 55 ± 20 g/m2.7; P = 0.003, paired t-test). A higher proportion of patients showing LVMi
reduction was observed in the m-TOR group (53.3 versus 29.3%, P = 0.048) at the study end. In addition, only 56% of the
m-TOR patients had LVH at the study end compared to 77% of the control group (P = 0.047). A significant change from
baseline in deceleration time in early diastole was observed in the m-TOR group compared with the control group
(P = 0.019).
Conclusions: Switching from CNI to m-TOR therapy in non-diabetic KT patients may regress LVH, independently of
blood pressure changes and follow-up time. This suggests a direct non-hemodynamic effect of m-TOR drugs on
cardiac mass.
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Left ventricular hypertrophy (LVH) is a very prevalent
clinical-pathological entity after kidney transplantation
(KT), and is a significant predictor of long-term adverse
KT outcome [1]. Classical and nontraditional risk factors
inherent to KT may participate in its pathogenesis [2].
Thus, regression of LVH is an important therapeutic tar-
get in order to optimize survival rates in these patients.
Mammalian target of rapamycin (m-TOR) inhibitors
may inhibit cardiac growth by antiproliferative effects. In-
deed, inhibition of the proliferation signal with sirolimus* Correspondence: domingohernandez@gmail.com
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article, unless otherwise stated.(SRL) led to regression of pressure load-induced LVH in
animal models [3-5]. In addition, nonrandomized con-
trolled trials have shown that conversion from calcineurin
inhibitors (CNI) to SRL may regress LVH in KT patients
[6,7]. More recently, a randomized controlled study dem-
onstrated that the use of everolimus (EVL) plus a reduced
exposure of cyclosporine (CsA) proved effective in regres-
sing LVH in KT recipients [8]. However, none of these
studies included patients who had received renin-
angiotensin system (RAS) blockers together with the
m-TOR inhibitors during the first post-conversion year.
RAS blockers are frequently used in KT recipients as
cardio-protective and reno-protective drugs and, indeed,
their use has been associated with regression of LVH after
KT [9,10]. Thus, a potential additive effect on cardiac masstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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RAS blockers, are administered together in this particular
population. Finally, little information has been provided
about the effect of m-TOR inhibitors on Doppler-derived
diastolic function [11]. Angiotensin II leads to prolonged
diastolic filling [12], and changes in diastolic function
might be expected when both RAS blockers and m-TOR
inhibitors concur in these patients.
In consonance with these arguments, we conducted a
longitudinal study to assess morphological and func-
tional echocardiographic changes after conversion from
CNI to m-TOR inhibitor drugs in nondiabetic KT pa-




This 1-year longitudinal nonradomized controlled study
involved nondiabetic KT patients who were switched
from a CNI (CsA or tacrolimus) to an immunosuppres-
sive regimen based on SRL or EVL plus mycophenolate
mofetil and steroids, in accordance with clinical practice.
Thus, inclusion criteria in the cohort were: 1) clinical indi-
cation for conversion due to either biopsied chronic allo-
graft dysfunction or non-melanoma skin cancer; 2) stable
renal function (serum creatinine <2.5 mg/dL); 3) 24-hour
urinary protein excretion <500 mg/day; and 4) signed in-
formed written consent. Exclusion criteria were: 1) pre-
existing lung or heart disease such as chronic respiratory
disease, valvular abnormalities, ischemic heart disease and
congestive heart failure; 2) impaired renal function (serum
creatinine >2.6 mg/dL); or 3) proteinuria >500 mg/day.
The patients underwent two echocardiographic studies
to examine the structural and functional changes in LV
mass after the first post-conversion year. In accordance
with our daily clinical practice in KT recipients, all the
patients received RAS blockers (angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers) prior
to inclusion in this study.
Patients and follow-up study
A total of 46 consecutive non-diabetic KT recipients
who were converted from a CNI to a m-TOR inhibitor
between February 1, 2010 and January 31, 2012 were ini-
tially enrolled in this study. The main reasons for conver-
sion were non-melanoma skin cancer (n = 30) and chronic
allograft dysfunction (n = 16). Sixteen patients were ex-
cluded due to m-TOR-related side effects after conversion
(n = 9) or withdrawal of consent (n = 7) during follow-up.
Thus, the final cohort involved 30 patients who completed
the 1-year observation period.
A control group was composed of 58 age-matched KT
recipients without diabetes and with a similar time after
grafting who received immunosuppressive therapy basedon CNIs. All also received RAS blockers during the
study period.
The goal of antihypertensive therapy was to obtain a
blood pressure ≤130/80 mmHg in both groups during
the study. Thus, antihypertensive agents, other than RAS
blockers, were adjusted to achieve this blood pressure con-
trol during the follow-up as in standard clinical practice.
Medical record review was performed according to
Spanish law with reference to clinical data confidenti-
ality. This study was approved by the Ethics Committee
of Carlos Haya University Hospital and was conducted
according to the Declaration of Helsinki. Each patient gave
written informed consent to participate in the study.
Laboratory measurements
Blood sampling for the measurement of routine and
other special biochemical measurements was performed
before the echocardiographic studies. Titration of m-
TOR drugs was tailored twice monthly in an attempt to
keep EVL and SRL trough levels between 4–7 ng/mL.
The daily urinary protein excretion rate was also assessed
at baseline and then monthly.
Echocardiography
Using standard methods, M-mode, two-dimensional and
color flow Doppler echocardiograms were performed by
a single experienced cardiologist (DG) at baseline and
after 12 months in both groups, blinded to the clinical
characteristics of the participants. Echocardiograms were
obtained with the patient in the left decubitus position
with 30° head inclination, using an ultrasonoscope sys-
tem (Philips iE33) equipped with a 1- to 5- MHz versatile
(X5-1) transducer. All echocardiographic measurements
were undertaken following the recommendations of the
American Society of Echocardiography [13]. Intraobserver
variability was less than 5%.
Left ventricular end-diastolic diameter (LVEDD), pos-
terior wall thickness (PWT), and the interventricular
septum thickness (IVS) were measured at end diastole.
Left ventricular mass (LVM) was defined according to
the equation [14]: LVM = 0.80 × 1.04 × [(IVS + PWT +
LVEDD)3)- LVEDD3] + 0.6 g. and then indexed for
height2.7, which has been documented as the reliable in-
dexation for patients with renal failure [15]. LVH was
defined by a LVMi >49.2 g/m2.7 and >46.7 g/m2.7 in ac-
cordance with previously reported cutoff values for men
and women, respectively [16]. Left ventricular relative
wall thickness was calculated as (IVS + PWT)/LVEDD
[17]. The percentage of fractional shortening of the left
ventricle was calculated to evaluate systolic function by the
formula LVEDD-LVESD/LVEDD × 100, where LVESD is
left ventricular end-systolic diameter. The left ventricu-
lar ejection fraction was also assessed. The Doppler in-
dexes measured were deceleration time of flow velocity







Age (y) 58.2 ± 13.7 54.5 ± 14 0.239
Gender (Male/Female) 21/9 37/21 0.560
Cause of CKD
(GN/PKD/HKD/IN/Other) 9/4/1/3/13 23/4/6/9/16 0.370
Time from transplant to
study end (mo)
89.7 ± 72 82 ± 30 0.574
Systolic blood pressure
(mm Hg)
126 ± 11 130 ± 12 0.122
Diastolic blood pressure
(mm Hg)
73 ± 9 76 ± 8 0.129
Serum creatinine (mg/dL) 1.56 ± 0.3 1.5 ± 0.4 0.464
No. of antihypertensive
drugs
1.6 ± 1 1.8 ± 0.8 0.224
Hemoglobin (g/dL) 13 ± 1.5 13.6 ± 1.8 0.101
Cholesterol (mg/dL) 177 ± 31 189 ± 40 0.124
Triglycerides (mg/dL) 140 ± 60 165 ± 80 0.103
Uprot (mg/24 h) 275 ± 232 32 ± 47 0.000
BMI (kg/m2) 28 ± 4.7 28.3 ± 4.4 0.736
Values are shown as mean ± SD or absolute values. To convert creatinine in
mg/dl to μmol/L, multiply by 88.4; Hemoglobin in g/dl to g/L, multiply by 10;
cholesterol in mg/dL to mmol/L, multiply by 0.02586; triglycerides in mg/dL to
mmol/L, multiply by 0.01129.
Abbreviations: IN, Interstitial nephropathy; CKD, chronic kidney disease; GN,
glomerulonephritis; PKD, polycystic kidney disease; HKD, hypertensive kidney
disease; IN, interstitial nephropathy; BMI, body mass index; Uprot, daily urinary
protein excretion.
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laxation time (LVIRT) in ms, and peak early diastolic
velocity (E) and peak atrial diastolic velocity (A) in cen-
timeters per second. In addition, the E/A ratio was also
calculated.
Outcome
The primary outcome was determined as percent change
in LVMi (ΔLVMi) between the two echocardiographic
studies ([baseline value – final value] × 100/baseline value).
Statistical analysis
Data are presented as mean ± SD or median ± interquartile
range. Comparisons of continuous variables between the
two groups were made by means of Student’s t test or
Mann–Whitney U test in the case of nonparametric
distribution. Paired t-test (or Wilcoxon signed-rank test
depending on distribution of data) was used for intra-
group comparisons. The Chi-square test or Fisher exact
test, when appropriate, were used for inter-group com-
parisons of categorical variables. Multiple regression
analysis was performed to determine independent predic-
tors of the final ΔLVMi from baseline. We also screened
the following variables: age, gender, primary cause of kid-
ney disease, follow-up time, use of RAS blockers, body
mass index (BMI kg/m2), blood pressure, hemoglobin
levels, renal function, baseline LVMi, and changes from
baseline of blood pressure, BMI and hemoglobin levels.
Co-linearity and the assumption of normality were never
violated. Computations were made by SPSS 15.0 for
Windows (SPSS Inc., Chicago, IL). A P value less than 0.05
was considered significant.
Results
Of the 30 patients in the m-TOR group who completed
the 1-year observation period, 19 were switched to SRL
and 11 to EVL. No patients who ended the study period
experienced acute rejection. The median time from trans-
plantation to m-TOR therapy conversion was 64 months
(interquartile range 16–105 months).
Table 1 summarizes the clinical and demographic data
for the two groups. As expected, a higher baseline
24-hour urinary protein excretion was observed in the
m-TOR inhibitor group because chronic allograft dys-
function was present in 16 patients prior to conversion.
No significant differences were found in other clinical
variables such as age, gender, cause of renal disease,
blood pressure, number of antihypertensive drugs, BMI,
serum creatinine, hemoglobin levels, lipid profile or time
from transplantation to the end of the study. The number
of baseline antihypertensive drugs was similar in the two
study groups.
No significant differences were found between the
two groups with regard to baseline ecochardiographicmorphological data. Furthermore, the prevalence of LVH
was similar among patients with and without m-TOR in-
hibitors (Table 2). However, the m-TOR patients showed a
longer peak atrial diastolic velocity compared with the con-
trol group. As a consequence, the E/A ratio was signifi-
cantly higher in the control group.
Comparisons of changes in clinical data at the end of
the follow-up between the two groups are shown in
Table 3. Both groups were receiving a similar proportion
of other antihypertensive drugs at the study end (56 versus
65%; P = 0.3779), but a non-significant reduction of blood
pressure was more evident in patients switched from CNI
to m-TOR inhibitors. As expected, a significant increase
in triglyceride levels was observed in the m-TOR group,
even though 40% of the patients received lipid-lowering
drugs. In addition, a significant increase in proteinuria
values was also documented in patients who received m-
TOR compared with the control group. Lastly, no signifi-
cant differences were observed for BMI, cholesterol con-
centration, or hemoglobin and serum creatinine levels
between the two groups.
The m-TOR group showed a more significant reduction
in LVMi after 1 year (from 62 ± 22 to 55 ± 20 g/m2.7;
P = 0.003, paired t-test), resulting mainly from a significant
Table 2 Baseline morphological and functional






LAD (mm) 38.4 ± 5.5 39.5 ± 5.5 0.379
LVEDD (mm) 48.2 ± 5.4 49.7 ± 6 0.259
IVS (mm) 12.7 ± 2.4 13 ± 2.7 0.259
PWT (mm) 12.3 ± 2.2 12.1 ± 2.1 0.832
RWT 0.52 ± 0.1 0.51 ± 0.1 0.948
EF (%) 69.7 ± 6 71.5 ± 8 0.272
FS (%) 46 ± 8.5 43 ± 7 0.102
LVMI (g/m2.7) 62 ± 22 65 ± 17 0.471
LVH prevalence (%) 77 86 0.259
Peak E (cm/sec) 0.80 ± 0.2 0.73 ± 0.2 0.099
Peak A (cm/sec) 0.92 ± 0.3 0.7 ± 0.2 0.000
E/A ratio 0.92 ± 0.3 1.1 ± 0.4 0.014
DT (msec) 215.5 ± 89 236 ± 64 0.673
LVIRT (msec) 99.3 ± 23 100.6 ± 39 0.847
Values are shown as mean ± SD or percentages.
Abbreviations: LAD, left atrial diameter; LVEDD, left ventricular end-diastolic
diameter; IVS, interventricular septal thickness; PWT, posterior wall thickness;
RWT, relative wall thickness; EF, left ventricular ejection fraction; FS, left ventricular
fractional shortening; LVMI, left ventricular mass index; LVH, left ventricular
hypertrophy; Peak E, peak early diastolic flow velocity; peak A, peak late diastolic
flow velocity; E/A ratio, ratio of early to late diastolic flow; DT deceleration time of
E wave; LVIRT, left ventricular isovolumetric relaxation time.
Table 3 Changes in clinical parameters from baseline to 12 m
Δ, m-TOR group (P) Δ, Cont
BMI (kg/m2) 1.37 ± 7 0
(0.2)
Systolic blood pressure (mmHg) −1.7 ± 12 0.
(0.6)
Diastolic blood pressure (mmHg) −2.8 ± 16 0.7
(0.7)
Serum creatinine (mg/dL) −0.44 ± 22 −0
(0.7)
Hemoglobin (g/dL) −7.6 ± 6.6 −
(0.0001) (
Uprot (mg/24 h) −278 ± 572 −6
(0.003)
Cholesterol (mg/dL) −12.1 ± 22 −5
(0.01)
Triglycerides (mg/dL) −24.6 ± 58 6
(0.08) (
Δ, percent increase or decrease from baseline ([baseline value – final value] x 100/b
P values for the differences between final and baseline absolute values, and 95% co
To convert serum creatinine in mg/dL to mol/L, multiply by 88.4; hemoglobin in g/d
triglycerides in mg/dL to mmol/L, multiply by 0.01129.
Abbreviations: BMI, body mass index; Uprot, daily urinary protein excretion.
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2.2 mm; P = 0.002, paired t-test) and posterior wall (12.2 ±
2.2 to 11.3 ± 2 mm; P = 0.001; paired t-test). On the other
hand, a smaller change in LVMi was documented in the
control group at the study end (Figure 1 and Table 4). As a
result, a higher proportion of patients showing a reduction
(>10%) in LVMi was observed in the m-TOR group (53.3
versus 29.3%, P = 0.048) after 12 months of follow-up. In
addition, at the end of the study only 56% of patients met
criteria for LVH whereas 77% of the control group met
these criteria (P = 0.047). Finally, a significant increase in
the peak early diastolic velocity was only observed in the
m-TOR group (0.80 ± 0.22 to 0.92 ± 0.27 cm/sec; P = 0.034;
paired t-test).
Table 4 displays the changes in echocardiographic pa-
rameters from baseline to 12 months. A clinically more
pronounced but non-significant change in LVMi was
seen in the m-TOR group compared with the control
group. Of note, a significant change in DT from baseline
was observed in the m-TOR group compared with the
control group. Moreover, a trend toward a greater change
in peak early diastolic velocity was also documented in the
m-TOR group. No other differences were observed from
baseline between the two study groups.
By backward linear regression analyses, baseline LVMi
(β = 0.334, P = 0.004) and m-TOR therapy (β = 0.236;
P = 0.043) were significantly associated with LVMi changes,
after adjusting for age, gender, blood pressure, hemoglobinonths in both groups
rol group (P) Δ, Effect (m-TOR vs.Control), (95% CI) P value
.2 ± 5 1.1 ± 1.3 0.459
(0.7) (−1.8 to 4)
98 ± 12 2.6 ± 2.7 0.324
(0.4) (−8 to 2.7)
± 14.7 −3.6 ± 3.5 0.326
(0.3) (−10 to 3.6)
.55 ± 24 0.1 ± 5.4 0.985
(0.4) (−10.8 to 11)
6 ± 16 −1.7 ± 2.6 0.503
0.002) (−6.8 to 3.4)
.1 ± 98 −271.6 ± 116 0.028
(0.4) (−511 to −32)
.9 ± 21 −6.2 ± 5.2 0.243
(0.15) (−17 to 4.3)
.3 ± 33 −31 ± 12.3 0.017
0.010) (−56 to −5.8)
aseline value). Data are expressed as mean ± SD. Values in parentheses are
nfidence intervals for the control versus m-TOR group effect.
L to g/L, multiply by 10; cholesterol in mg/dL to mmol/L, multiply by 0.02586;
Figure 1 Change in left ventricular mass index. Change in left
ventricular mass index (LVMi; mean ± SEM) in 30 renal transplant
recipients on m-TOR therapy (filled squares) and 58 controls (open
squares) over a 1-year observation period. *P = 0.003 and **P = 0.052
compared with baseline LVMi.
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for 40% of the total variation in ΔLVMi.
Discussion
The most relevant finding of this prospective cohort
study was that conversion from a CNI to m-TOR inhibi-
tor is associated with marked LVH regression in non-
diabetic KT recipients receiving RAS blockers, whereas
only a modest LVMi change was observed in the control
group. This reduction was achieved mainly by redu-
cing the ventricular wall thickness and interventricular
septum. No differences were found in terms of protein-
uria, renal function, hemoglobin levels, incidence of ad-
verse events, lipid profile or LVMi change between SRL
and EVL after conversion (data not shown). As a conse-
quence, a significantly higher proportion of patients
showed a reduction in LVH in the m-TOR group com-
pared with the control group. In addition, regression of
LVH was independent of blood pressure and the post-
transplant time, among other risk factors affecting LV
mass. We cannot rule out, though, that substantially dif-
ferent hemodynamic effects between the two treatment
groups (CNI versus m-TOR therapy), affecting only mod-
estly blood pressure, could modulate LVM changes at the
end of the follow-up. Indeed, non significant differences in
brachial pressure between different antihypertensive regi-
mens may lead to significant changes in LVM by increas-
ing central aortic pressure, as previously reported [18,19].
The change in immunosuppression was based on previ-
ously reported beneficial effects of replacing CNI with
m-TOR inhibitors when side effects, chronic allograft
dysfunction or skin cancer occur in KT patients during
follow-up, as in our study. In order to minimize coexist-
ent abnormalities that could affect cardiac growth, we
only included non-diabetic patients with an acceptable
renal graft function and absence of mild proteinuria.Our results are consistent with findings derived from
animal model studies demonstrating that the use of a
SRL dosage similar to that prescribed in KT was associ-
ated with regression of pressure-induced cardiac hyper-
trophy by means of antiproliferative mechanisms [3-5].
In addition, Paoletti et al. demonstrated in controlled
studies that both SRL and EVL regress left ventricular
mass in KT recipients [6-8]. However, no patient re-
ceived combined treatment with m-TOR inhibitors and
RAS blockers during the first 12 months post-conversion.
RAS blockers are widely used in KT patients and have
been associated with LVH regression, especially when the
machinery of cardiac growth is activated, as reported in
KT recipients [9].
Currently, CNIs are the cornerstone of immunosup-
pressive treatment for KT patients. These drugs may
result in the development of cardiac hypertrophy and
myocardial fibrosis by stimulating both circulating and
local RAS. Angiotensin II activates m-TOR-p70 riboso-
mal S6 kinase, which regulates protein synthesis in car-
diac myocytes [20,21]. In addition, m-TOR drugs may
attenuate the angiotensin II-induced increase in protein
synthesis by blocking phosphorylation of the p-70 ribo-
somal S6 protein involved in cardiac growth [20,22]. In
consonance with these findings, RAS blockers are effect-
ive in reducing LVH after KT, independently of blood
pressure [9,23]. In a controlled clinical trial evaluating
the effects of conversion from CNIs to SRL in KT recipi-
ents, Paolleti et al. observed a significant regression of
LVMi in patients treated with SRL and RAS blockers at
the third year of follow-up, but RAS blockers were only
prescribed after the first post-conversion year [7]. In
contrast, a recent clinical trial in KT recipients com-
paring EVL-based versus CsA-based immunosuppres-
sion found no differences in LV mass between the two
groups, but the CsA group received a significantly higher
proportion of antihypertensive drugs, including RAS
blockers. Furthermore, RAS blockers were not used in the
EVL-group [24].
In our study, all the patients in the m-TOR group had
received RAS blockers prior to conversion, according to
our daily clinical practice. Thus, both types of drugs, m-
TOR and RAS blockers were administered in this group
throughout the whole follow-up period after conversion.
Our results suggest that, in non-diabetic renal transplant
recipients, a more pronounced effect of m-TOR drugs
on left ventricular mass might be expected in the pres-
ence of RAS blockers. In other words, a synergistic effect
on regression of LVH seems plausible when both kinds
of drugs are administered in this population, especially
after suppression of CNI. Whether a similar effect on
cardiac mass would be observed in KT recipients on
m-TOR inhibitors therapy but without additional RAS
blockers cannot be determined from this study.
Table 4 Changes in echocardiographic parameters from baseline to 12 months in both groups
Δ, m-TOR group (P) Δ, Control group (P) Δ Effect (m-TOR vs Control) (95%CI) P value
LAD (mm) 0.90 ± 15 0.30 ± 14 0.59 ± 3.4 0.859
(0.4) (0.6) (−6 to 7.3)
LVEDD (mm) 45.8 ± 10 44 ± 9 1.8 ± 2.1 0.428
(0.7) (0.2) (−2.5 to 5.8)
IVS (mm) 5.3 ± 8.5 3.1 ± 16 2.2 ± 2.7 0.427
(0.002) (0.04) (−3.1 to 7.4)
PWT (mm) 7 ± 10 4.9 ± 14 2.1 ± 2.7 0.415
(0.001) (0.01) (−3.1 to 7.5)
RWT 4.8 ± 14 5 ± 17 0.2 ± 3.7 0.949
(0.026) (0.035) (−7.1 to 7.6)
EF (%) 6.6 ± 11 0.5 ± 16 6.1 ± 3.6 0.101
(0.7) (0.2) (−1.2 to 13)
FS (%) −1.05 ± 21 −8 ± 25 7.1 ± 5.4 0.197
(0.2) (0.02) (−3.7 to 18)
LVMi (g/m2.7) 8.4 ± 18 3.8 ± 16 4.5 ± 3.9 0.255
(0.003) (0.052) (−3.4 to 12)
Peak E (cm/sec) −19.4 ± 43 −6.4 ± 25.6 −13 ± 9 0.135
(0.034) (0.4) (−30 to 4.6)
Peak A (cm/sec) −11.1 ± 33 −9.3 ± 27 −1.7 ± 7 0.808
(0.3) (0.1) (−16 to 12)
E/A ratio −0.06 ± 0.34 −0.001 ± 0.34 −12.6 ± 9.8 0.429
(0.3) (0.9) (−32 to 7)
DT (msec) −18.2 ± 9 −5 ± 40 −13 ± 7.8 0.019
(0.05) (0.8) (−29 to 3.5)
LVIRT (msec) −10.3 ± 33 −3 ± 31 −7.1 ± 7.5 0.341
(0.4) (0.5) (−22 to 8)
Δ, percent increase or decrease from baseline ([baseline value – final value] x 100/baseline value). Values are expressed as mean ± SD; values in parentheses are
P values for the differences between final and baseline absolute values, and 95% confidence intervals for the control versus m-TOR group effect.
Abbreviations: LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; IVS, interventricular septal thickness; PWT, posterior wall thickness; RWT,
relative wall thickness; FS, left ventricular fractional shortening; LVMI, left ventricular mass index; Peak E, peak early diastolic flow velocity; peak A, peak late
diastolic flow velocity; E/A ratio, ratio of early to late diastolic flow; DT deceleration time of E wave; LVIRT, left ventricular isovolumetric relaxation time.
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ciated with LVH in uremic patients [22]. m-TOR inhibi-
tors and RAS blockers are potent antifibrotic agents
[20,25]. We cannot rule out a greater response to the ef-
fect of m-TOR drugs in patients with both myocardial
fibrosis and histological features of chronic allograft dys-
function. However, the fact that the control patients,
who mostly received RAS blockers, showed a lesser re-
duction in cardiac mass with an allograft function simi-
lar to the m-TOR group after 12 months makes this
unlikely.
Cardiac hypertrophy and myocardial fibrosis have been
associated with CNI treatment, contributing to dia-
stolic abnormalities and elevation of filling pressures [11].
Inhibition of m-TOR reduces cardiac growth and fibrosis.
LVH reduction after conversion from CNI drugs to
m-TOR therapy was accompanied by a change in passive
ventricular filling pattern, as evidenced by a significantDT change from baseline. Likewise, a more pronounced
change in peak early diastolic velocity was observed in
the m-TOR group compared with the control group, who
had a higher baseline E/A ratio. In this respect, a previ-
ous report has demonstrated that SRL improves parame-
ters of diastolic function in heart transplant patients [11].
However, to our knowledge, no reports have previously
documented diastolic function changes in KT recipients
who received both m-TOR therapy and RAS blockers.
Given the effects of angiotensin II on diastolic filling [12],
a change in early diastolic function might occur in KT
recipients with an activated RAS, as evidenced in our
study. We cannot rule out that assessment of diastolic
function by pulsed-wave tissue Doppler echocardiog-
raphy, such as evaluation of mitral annulus velocity, could
elucidate more accurately the changes in the diastolic
performance than standard echocardiography. Taken
together, we speculate that combined administration of
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tion of both cardiac fibrosis and angiotensin-induced
hypercontractility, contributing to optimizing cardiac
remodeling and distensibility, as well as the diastolic
filling pattern. Whether this finding is associated with
a lower risk of post-transplant heart failure in the long
term is uncertain.
As expected, a slight but significant increase in both
the urinary protein excretion rate and lipid levels was
observed in patients on m-TOR therapy, which may be
clinically relevant given the association of low-grade pro-
teinuria and hyperlipidemia with increased cardiovas-
cular risk in KT recipients [26,27]. Nevertheless, the
proportion of patients receiving statins and the number
of individuals with proteinuria greater than 0.5 g/day
were similar in the two groups after the one-year obser-
vation period (data not shown). In theory, this suggests
that patients on m-TOR therapy should not be exposed
to a higher cardiovascular risk. Future longitudinal and
prospective studies will be needed to clarify the prognos-
tic significance of these findings.
This study has some limitations, the most important
of which is that it was not a blinded, randomized
study. Secondly, we studied a highly selected cohort of
KT recipients who presented transplant-related clinical
complications such as chronic allograft dysfunction or
non-melanoma skin cancer, which could limit the gen-
eralizability of our findings. In addition, our study was
a single-center trial and the changes in LVM could be
the effect of intrapatient variability. However, all the
subjects in the final cohort completed the investigation
and prospective echocardiographic examinations were
performed after conversion by the same cardiologist, with
an intraobserver variability lower than 5%. This, in theory,
should minimize the risk of misleading measurements.
Moreover, control patients, who received only CNI as the
main immunosuppressive therapy, underwent two echo-
cardiograms during the same study period, though the
changes in LVH reduction were more modest as com-
pared with the m-TOR group. Finally, regression of the
mean phenomenon may have occurred in this study, but
the results were adjusted for baseline LVMi as a predictor
variable, which makes it unlikely.
Conclusion
In conclusion, conversion from CNI to m-TOR therapy
in non-diabetic KT recipients was associated with re-
gression of LVH, independently of other risk factors for
cardiac growth. In addition, a change in diastolic filling
pattern may be achieved with this strategy, possibly linked
to changes in cardiac remodeling and distensibility. Future
large randomized studies are needed to determine whether
m-TOR drugs should be used as first line therapy to
optimize cardiac remodeling in this population.Abbreviations
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